Medicines

NICE recommends Tremfya

NICE has approved Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis

Paracetamol, pregnancy and language

Exposure to paracetamol during pregnancy seems to increase the risk of language delay in girls, but not boys

Warfarin may cut cancer risk

Research suggests warfarin may have anti-cancer potential. Could this have implications for anticoagulation patients?

Tremfya launched for psoriasis

Janssen has launched guselkumab (Tremfya) for adults with moderate to severe plaque psoriasis

Quadrivalent flu jab launched

Sanofi Pasteur recently launched a quadrivalent influenza vaccine in the UK that protects against two A and two B strains

New antibiotic launched

Pfizer has launched Zavicefta (ceftazidime-avibactam) for adults hospitalised with serious infections

Verapamil for rhinosinusitis?

Verapamil dramatically improves symptom scores in patients with chronic rhinosinusitis and nasal polyps

NSAIDs and paracetamol linked to hearing loss

NSAIDs and paracetamol might increase the risk of hearing loss, according to an analysis of 55,850 women

Rotavirus vaccine is preventing gastroenteritis in infants

Infant rotavirus vaccine reduces the number of episodes of acute gastroenteritis by up to half and saves £12.5m a year

Teva launches reformulated levothyroxine range

Teva has launched a reformulated version of levothyroxine, including two previously unavailable strengths

Xultophy approved for renal impairment

Xultophy has been approved for adults with type 2 diabetes and moderate renal impairment

Update: media scare stories cutting statin use?

Media stories questioning the safety of statins are causing people to stop taking the drugs

Update: Enstilar – new psoriasis drug

Enstilar (calcipotriol and betamethasone dipropionate) is a new topical, alcohol-free, foam spray for plaque psoriasis

Massive increase in ADHD prescribing

Prescriptions for ADHD drugs in the UK increased by almost 800 per cent between 2000 and 2015

Benzodiazepines could significantly increase flu risk

Benzodiazepines may increase mortality more than 20-fold in people with influenza-like illness, new research finds

Actavis adds gliclazide 40mg

Actavis has added gliclazide 40mg tablets alongside the existing 80mg tablet offer

New ticagrelor dose

Marketing authorisation has been granted for a 60mg dose of ticagrelor for patients who have suffered a heart attack  

New lung cancer drug

The European Commission has granted marketing authorisation for necitumumab (Portrazza) for lung cancer

Ezetimibe indication widened

The MHRA recently extended the indication for ezetimibe (Ezetrol)

Dementia script numbers rise but costs fall

The number of prescriptions for drugs for Alzheimer’s disease rose more than six-fold over the past decade

Previous 1 2 3 4 Next

Latest

BREAKING: High Court rules in favour of NPA in P2U contact detail…

Pharmacy2U has failed in a legal bid to obtain the contact details of thousands of independent community pharmacies

Keith Ridge to lead NHS overprescribing review

The review is aimed at bringing down the health service’s medicines spend and limiting harm to patients

Views

Tales of Yuletide woe but let's raise a glass to pharmacy

By Richard Thomas, editor, Pharmacy Magazine. Christmas and the New Year is traditionally a time of hope and renewal, b...

Popular

Autumn 2018 budget announced

Chancellor Philip Hammond has today (Monday 29 October) delivered his 2018 budget, describing it as bringing an end to t...

NHS workforce increases by 1.6 per cent in a year

A total of 1,230,000 FTEs were employed by the health service in England across NHS Trusts, CCGs, NHS support organisati...

Men’s health: An uphill struggle

At a time when we’re supposedly more health aware than ever before, what could be causing men to neglect their health?



This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.